KHN-921 gains IND clearance for MYBPC3-associated HCM

May 14, 2026

Chengdu Origen Biotechnology Co. Ltd. and Vanotech Ltd. have announced IND clearance by the FDA for KHN-921 for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations.

BioWorld Science Regulatory Cardiovascular Gene therapy FDA IND

Today's news in brief

BioWorld

BioWorld briefs for July 7, 2026.

CINP 2026: Prenatal and adolescent stress shape brain vulnerability

BioWorld Science

Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...

Illustration of brain and brain waves, concept of focal seizure

Hyperexcitability may be joint problem in epilepsy, dementia

BioWorld

The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

In the clinic for July 6, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.